144598-75-4 | Paliperidone

Packsize	Purity	Availability	Price	Discounted Price
5mg	>98%(HPLC)powder	in stock	$62.00	$44.00
25mg	>98%(HPLC)powder	in stock	$94.00	$66.00
50mg	≥98%	in stock	$178.00	$125.00
200mg	>97.0%(T)	in stock	$215.00	$150.00
1g	>97.0%(T)	in stock	$742.00	$519.00

Description

• Catalog Number: AA72143
• Chemical Name: Paliperidone
• CAS Number: 144598-75-4
• Molecular Formula: C23H27FN4O3
• Molecular Weight: 426.4839
• MDL Number: MFCD00871802
• SMILES: Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2O

Computed Properties

• Complexity: 764
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.2

Literature

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

  JAMA psychiatry 20150801

• Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20121203

• Paliperidone extended release: in adolescents with schizophrenia.

  Paediatric drugs 20121201

• An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.

  Drug metabolism and disposition: the biological fate of chemicals 20121101

• Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.

  Progress in neuro-psychopharmacology & biological psychiatry 20121001

• Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.

  Journal of clinical psychopharmacology 20121001

• An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate.

  The Annals of pharmacotherapy 20121001

• Solid phase microextraction and LC-MS/MS for the determination of paliperidone after stereoselective fungal biotransformation of risperidone.

  Analytica chimica acta 20120912

• Paliperidone for irritability in adolescents and young adults with autistic disorder.

  Psychopharmacology 20120901

• Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.

  International clinical psychopharmacology 20120901

• Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

  CNS drugs 20120901

• Second-generation long-acting injectable antipsychotic agents: an overview.

  Drug and therapeutics bulletin 20120901

• The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20120807

• Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

  Journal of pharmacokinetics and pharmacodynamics 20120801

• Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.

  Current medical research and opinion 20120801

• Paliperidone: a review of clinical trial data and clinical implications.

  Clinical drug investigation 20120801

• A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.

  The Journal of clinical psychiatry 20120801

• Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

  Pharmaceutical research 20120701

• Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.

  Expert opinion on drug metabolism & toxicology 20120701

• Paliperidone palmitate for schizophrenia.

  The Cochrane database of systematic reviews 20120613

• Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.

  Schizophrenia research 20120601

• Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.

  Journal of clinical psychopharmacology 20120601

• Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002-2010.

  Therapeutic drug monitoring 20120601

• Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

  Drugs 20120528

• Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.

  International journal of pharmaceutics 20120510

• Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study.

  International clinical psychopharmacology 20120501

• A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.

  Journal of affective disorders 20120501

• Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder.

  CNS drugs 20120501

• Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.

  Human psychopharmacology 20120501

• Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.

  Journal of clinical pharmacy and therapeutics 20120401

• Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

  The Journal of pharmacology and experimental therapeutics 20120401

• Practical guidelines on the use of paliperidone palmitate in schizophrenia.

  Current medical research and opinion 20120401

• Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.

  Therapeutic drug monitoring 20120401

• Catatonia and encephalopathy associated with paliperidone palmitate.

  Journal of clinical psychopharmacology 20120401

• A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in paliperidone active pharmaceutical ingredient and its pharmaceutical dosage forms.

  Journal of chromatographic science 20120401

• Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?

  Journal of cardiovascular pharmacology 20120301

• Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.

  PLoS medicine 20120301

• Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.

  Reviews on recent clinical trials 20120201

• Acute renal failure after paliperidone overdose: a case report.

  Journal of clinical psychopharmacology 20120201

• A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.

  The Australian and New Zealand journal of psychiatry 20120201

• Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.

  Progress in neuro-psychopharmacology & biological psychiatry 20120110

• Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.

  Journal of affective disorders 20120101

• QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.

  Human psychopharmacology 20120101

• Oral-paliperidone-induced tardive dyskinesia: a case report.

  General hospital psychiatry 20120101

• Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120101

• Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.

  BMC clinical pharmacology 20120101

• The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving.

  Journal of medical economics 20120101

• [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].

  Rivista di psichiatria 20120101

• In situ nondestructive sediment characterization and resuspendability evaluation of concentrated aqueous paliperidone palmitate suspensions in prefilled syringes by low-field one-dimensional pulsed-field gradient NMR profilometry.

  Pharmaceutical development and technology 20120101

• A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

  BMC psychiatry 20120101

• Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

  Journal of medical economics 20120101

• Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study.

  Health and quality of life outcomes 20120101

• Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.

  PloS one 20120101

• Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.

  International journal of general medicine 20120101

• [Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20120101

• Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.

  Human psychopharmacology 20120101

• Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

  Annals of general psychiatry 20120101

• Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.

  Patient preference and adherence 20120101

• Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.

  Clinical pharmacology : advances and applications 20120101

• Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.

  Clinical neuropharmacology 20120101

• Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

  Neuropsychiatric disease and treatment 20120101

• Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents.

  Innovations in clinical neuroscience 20120101

• Aripiprazole reverses paliperidone-induced hyperprolactinemia.

  Actas espanolas de psiquiatria 20120101

• A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.

  Biological psychiatry 20111215

• Social interaction and drug attitude effectiveness in patients with schizophrenia.

  The Psychiatric quarterly 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.

  Psychopharmacology 20111001

• Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

  Schizophrenia research 20111001

• Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.

  Journal of clinical psychopharmacology 20111001

• Enantioselective fungal biotransformation of risperidone in liquid culture medium by capillary electrophoresis and hollow fiber liquid-phase microextraction.

  Electrophoresis 20111001

• Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.

  CNS drugs 20111001

• Paliperidone palmitate in a child with autistic disorder.

  Journal of child and adolescent psychopharmacology 20111001

• Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.

  Journal of psychiatric research 20110901

• Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.

  British journal of pharmacology 20110901

• Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.

  Neuroscience letters 20110818

• The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods.

  Biochimica et biophysica acta 20110801

• Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

  Current medical research and opinion 20110801

• Osmotic-controlled release oral delivery system (OROS) paliperidone-related pruritic rash.

  Journal of clinical psychopharmacology 20110801

• A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.

  Innovations in clinical neuroscience 20110801

• Paliperidone overdose with delayed onset of toxicity.

  Annals of emergency medicine 20110701

• Species independence in brain tissue binding using brain homogenates.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters in human urine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

• A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20110601

• Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?

  Journal of cardiovascular pharmacology 20110601

• Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?

  Therapeutic drug monitoring 20110601

• Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.

  Schizophrenia research 20110601

• Paliperidone-related rabbit syndrome.

  Journal of clinical psychopharmacology 20110601

• Use of paliperidone in elderly patients with schizophrenia and schizoaffective disorder: a prospective open-label short-term pilot study.

  Journal of clinical psychopharmacology 20110601

• Oral paliperidone: a review of its use in the management of schizoaffective disorder.

  CNS drugs 20110601

• [Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110601

• A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

  Journal of psychopharmacology (Oxford, England) 20110501

• Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.

  The Journal of pharmacology and experimental therapeutics 20110401

• Paliperidone augmentation for treatment-resistant depression: a case report.

  Journal of clinical psychopharmacology 20110401

• Paliperidone-associated seizure after discontinuation of sodium valproate: a case report.

  Journal of clinical psychopharmacology 20110401

• Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.

  Journal of child and adolescent psychopharmacology 20110401

• Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

  The Journal of clinical psychiatry 20110401

• Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.

  Progress in neuro-psychopharmacology & biological psychiatry 20110330

• Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

  Journal of affective disorders 20110301

• Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.

  Current drug safety 20110201

• Change in employment status over 52 weeks in patients with schizophrenia: an observational study.

  Current medical research and opinion 20110201

• Paliperidone-induced leukopenia and neutropenia: a case report.

  Progress in neuro-psychopharmacology & biological psychiatry 20110115

• A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20110115

• Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110115

• Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.

  International clinical psychopharmacology 20110101

• Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

  BMC psychiatry 20110101

• Paliperidone-induced neuroleptic malignant syndrome.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

  BMC psychiatry 20110101

• Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study.

  General hospital psychiatry 20110101

• Paliperidone extended-release: does it have a place in antipsychotic therapy?

  Drug design, development and therapy 20110101

• Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.

  Annals of general psychiatry 20110101

• The use of videoconferencing with patients with psychosis: a review of the literature.

  Annals of general psychiatry 20110101

• Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia.

  Neuropsychiatric disease and treatment 20110101

• Acute dystonia associated with paliperidone overdose.

  Psychosomatics 20110101

• Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.

  BMC psychiatry 20110101

• Paliperidone-induced obsessive symptoms.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.

  Clinical neuropharmacology 20110101

• An in vitro evaluation of guanfacine as a substrate for P-glycoprotein.

  Neuropsychiatric disease and treatment 20110101

• The cost associated with administering risperidone long-acting injections in the Australian community.

  BMC health services research 20110101

• Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Manic symptoms during a switch from risperidone to paliperidone: a case report.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Clinical utility of the risperidone formulations in the management of schizophrenia.

  Neuropsychiatric disease and treatment 20110101

• [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].

  Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 20110101

• Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Tardive Tourette-like syndrome in a patient treated with paliperidone.

  The Journal of neuropsychiatry and clinical neurosciences 20110101

• Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions.

  Psychopharmacology 20101201

• Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.

  Therapeutic drug monitoring 20101201

• Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.

  Journal of clinical psychopharmacology 20101201

• The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.

  European journal of clinical pharmacology 20101101

• Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.

  International clinical psychopharmacology 20101101

• Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.

  The Journal of clinical psychiatry 20101101

• Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.

  Clinical therapeutics 20101101

• A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101009

• Paliperidone-induced mania-like symptoms: a case report.

  Progress in neuro-psychopharmacology & biological psychiatry 20101001

• Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients.

  Progress in neuro-psychopharmacology & biological psychiatry 20101001

• Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats.

  Brain research 20101001

• Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

  Journal of clinical psychopharmacology 20101001

• Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.

  Expert opinion on pharmacotherapy 20101001

• Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

  International clinical psychopharmacology 20100901

• A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100901

• New antipsychotic drugs: how do their receptor-binding profiles compare?

  The Journal of clinical psychiatry 20100901

• [9-hydroxy-risperidone (9OHRIS) prevents stress-induced β-actin overexpression in rat hippocampus].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20100901

• Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand.

  Clinical therapeutics 20100901

• Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.

  Progress in neuro-psychopharmacology & biological psychiatry 20100816

• [Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].

  Zhonghua yi xue za zhi 20100803

• Serum concentrations of paliperidone versus risperidone and clinical effects.

  European journal of clinical pharmacology 20100801

• Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100801

• Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.

  Basic & clinical pharmacology & toxicology 20100801

• One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.

  CNS spectrums 20100801

• Paliperidone extended release: a review of its use in the management of schizophrenia.

  Drugs 20100709

• Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

  Journal of psychopharmacology (Oxford, England) 20100701

• Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.

  Journal of psychopharmacology (Oxford, England) 20100701

• A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

  Journal of psychopharmacology (Oxford, England) 20100701

• Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.

  Psychopharmacology 20100701

• Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.

  Human psychopharmacology 20100701

• Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.

  Drugs of today (Barcelona, Spain : 1998) 20100701

• Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

  The international journal of neuropsychopharmacology 20100601

• Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration.

  Journal of clinical pharmacology 20100601

• Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.

  Journal of clinical pharmacology 20100601

• Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.

  Current medical research and opinion 20100601

• Hyperprolactinaemia during treatment with paliperidone.

  Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists 20100601

• A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

  Journal of clinical psychopharmacology 20100601

• Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.

  International journal of clinical pharmacology and therapeutics 20100601

• Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.

  International clinical psychopharmacology 20100501

• A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.

  The Journal of clinical psychiatry 20100501

• A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.

  Bipolar disorders 20100501

• Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.

  Sao Paulo medical journal = Revista paulista de medicina 20100501

• Paliperidone use in the elderly.

  Current drug safety 20100401

• Manic symptoms induced by paliperidone.

  Journal of clinical psychopharmacology 20100401

• Paliperidone overdose in a patient with schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20100317

• Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro.

  Journal of psychopharmacology (Oxford, England) 20100301

• A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

  European psychiatry : the journal of the Association of European Psychiatrists 20100301

• Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.

  Journal of clinical pharmacology 20100301

• Intramuscular paliperidone palmitate.

  CNS drugs 20100301

• Remission of drug-induced hepatitis after switching from risperidone to paliperidone.

  The American journal of psychiatry 20100301

• Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.

  Pharmacopsychiatry 20100301

• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  Schizophrenia research 20100201

• Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.

  Current medical research and opinion 20100201

• Possible neuroleptic malignant syndrome during paliperidone administration: a case report.

  Journal of clinical psychopharmacology 20100201

• Paliperidone for irritability in autistic disorder.

  Journal of child and adolescent psychopharmacology 20100201

• Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.

  Early intervention in psychiatry 20100201

• Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.

  Clinical therapeutics 20100201

• Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.

  Journal of affective disorders 20100101

• Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.

  International journal of clinical practice 20100101

• The pharmacokinetics of paliperidone versus risperidone.

  Psychosomatics 20100101

• Long-acting injectable antipsychotics: focus on olanzapine pamoate.

  Neuropsychiatric disease and treatment 20100101

• Once-monthly paliperidone injection for the treatment of schizophrenia.

  Neuropsychiatric disease and treatment 20100101

• Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database.

  Journal of medical economics 20100101

• Role of paliperidone extended-release in treatment of schizoaffective disorder.

  Neuropsychiatric disease and treatment 20100101

• Paliperidone-induced dystonic Dysphagia.

  The Journal of neuropsychiatry and clinical neurosciences 20100101

• [Non-fatal paliperidone overdose: a case report].

  Turk psikiyatri dergisi = Turkish journal of psychiatry 20100101

• Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detection.

  Journal of pharmaceutical and biomedical analysis 20091205

• Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.

  Journal of clinical psychopharmacology 20091201

• [Successful quetiapine therapy in psychotic patients with mood elevation].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20091201

• In brief: Injectable paliperidone palmitate for schizophrenia.

  The Medical letter on drugs and therapeutics 20091102

• Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.

  Journal of clinical pharmacology 20091101

• Second-generation antipsychotic long-acting injections: systematic review.

  The British journal of psychiatry. Supplement 20091101

• Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission?

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091028

• Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.

  Progress in neuro-psychopharmacology & biological psychiatry 20091001

• No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects.

  Human psychopharmacology 20091001

• Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis.

  Journal of clinical psychopharmacology 20091001

• The influence of hepatic impairment on the pharmacokinetics of paliperidone.

  International journal of clinical pharmacology and therapeutics 20091001

• Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders.

  Biomedical chromatography : BMC 20090901

• Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other 'inactivating antagonists'.

  Molecular pharmacology 20090901

• Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20090831

• Time resolved analysis of risperidone and 9-hydroxy-risperidone in hair using LC/MS-MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090815

• Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

  Psychiatry and clinical neurosciences 20090801

• Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response.

  Therapeutic drug monitoring 20090801

• Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.

  Schizophrenia research 20090801

• Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.

  Journal of medicinal chemistry 20090723

• Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.

  Current medical research and opinion 20090701

• The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

  Pharmacopsychiatry 20090701

• Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

  Human psychopharmacology 20090601

• Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

  The American journal of psychiatry 20090601

• Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

  Journal of clinical psychopharmacology 20090601

• In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

  Journal of chemical biology 20090601

• Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression.

  Psychopharmacology 20090501

• Secondary delusional parasitosis treated with paliperidone.

  Clinical and experimental dermatology 20090401

• An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

  Clinical pharmacology and therapeutics 20090401

• Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20090301

• Paliperidone in an adult patient with Asperger syndrome: case report.

  Pharmacopsychiatry 20090301

• Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.

  Expert opinion on drug delivery 20090301

• Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists.

  Molecular pharmacology 20090201

• Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.

  Current medical research and opinion 20090201

• Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers.

  International journal of clinical pharmacology and therapeutics 20090201

• [Psychiatry].

  Revue medicale suisse 20090114

• Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.

  Clinical pharmacokinetics 20090101

• Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

  Clinical interventions in aging 20090101

• Paliperidon mediated modification of cortical inhibition.

  Neuro endocrinology letters 20090101

• Antipsychotic induced catatonia: a case of probable dementia with Lewy bodies.

  The Journal of neuropsychiatry and clinical neurosciences 20090101

• Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

  Patient preference and adherence 20090101

• [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].

  Rivista di psichiatria 20090101

• Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy.

  Journal of chromatography. A 20081226

• The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.

  Journal of clinical psychopharmacology 20081201

• What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.

  Journal of psychiatric and mental health nursing 20081201

• Apparent seizure and atrial fibrillation associated with paliperidone.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081115

• Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

  British journal of clinical pharmacology 20081101

• Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.

  International clinical psychopharmacology 20081101

• Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.

  Brain research 20081003

• ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.

  Therapeutic drug monitoring 20081001

• Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.

  Therapeutic drug monitoring 20081001

• Paliperidone extended-release for the treatment of schizophrenia.

  Pharmacotherapy 20081001

• Antipsychotic drugs inhibit the function of breast cancer resistance protein.

  Basic & clinical pharmacology & toxicology 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• Risperidone long-acting injection: a review of its long term safety and efficacy.

  Neuropsychiatric disease and treatment 20081001

• Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia.

  Neuropsychiatric disease and treatment 20081001

• Choreatic symptoms during and after treatment with paliperidone and escitalopram.

  Pharmacopsychiatry 20080901

• [Paliperidone--a novel second-generation antipsychotic].

  Ugeskrift for laeger 20080825

• Toward prediction of alkane/water partition coefficients.

  Journal of medicinal chemistry 20080710

• Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.

  International clinical psychopharmacology 20080701

• Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080701

• Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.

  Current drug metabolism 20080601

• Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.

  Current medical research and opinion 20080601

• Paliperidone for treatment of schizophrenia.

  Schizophrenia bulletin 20080501

• Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

  The Journal of clinical psychiatry 20080501

• Paliperidone for schizophrenia.

  The Cochrane database of systematic reviews 20080416

• Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.

  Behavioural brain research 20080409

• Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

  Psychopharmacology 20080401

• Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20080401

• New drug update: 2007.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401

• Paliperidone: An improvement over risperidone?

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

• Paliperidone for schizophrenia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

• Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.

  Psychoneuroendocrinology 20080201

• Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.

  Expert review of neurotherapeutics 20080201

• Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

  Clinical therapeutics 20080201

• Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.

  Journal of clinical pharmacology 20080101

• Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20080101

• Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

  Clinical drug investigation 20080101

• Gateways to clinical trials. July-August 2008.

  Methods and findings in experimental and clinical pharmacology 20080101

• Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

  Drugs 20080101

• Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

  Biological psychiatry 20071215

• Paliperidone ER: a review of the clinical trial data.

  Neuropsychiatric disease and treatment 20071201

• Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.

  Journal of psychopharmacology (Oxford, England) 20071101

• The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.

  Expert opinion on drug safety 20071101

• Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071015

• Paliperidone: a new extended-release oral atypical antipsychotic.

  Expert opinion on pharmacotherapy 20071001

• Analytical and semipreparative enantioseparation of 9-hydroxyrisperidone, the main metabolite of risperidone, using high-performance liquid chromatography and capillary electrophoresis. Validation and determination of enantiomeric purity.

  Journal of chromatography. A 20070907

• Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.

  Psychopharmacology 20070901

• A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

  International clinical psychopharmacology 20070901

• Enantioselective analysis of the antipsychotic 9-hydroxyrisperidone, main metabolite of risperidone, by chiral capillary EKC using dual CDs.

  Electrophoresis 20070801

• Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

  Schizophrenia research 20070701

• Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.

  Human psychopharmacology 20070701

• Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

  Clinical therapeutics 20070701

• Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.

  Progress in neuro-psychopharmacology & biological psychiatry 20070630

• Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601

• Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.

  Journal of clinical psychopharmacology 20070601

• [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].

  Yao xue xue bao = Acta pharmaceutica Sinica 20070601

• Molecule of the month. Paliperidone.

  Drug news & perspectives 20070601

• Paliperidone extended-release tablets: a new atypical antipsychotic.

  Journal of psychosocial nursing and mental health services 20070501

• A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

  Pharmacopsychiatry 20070501

• Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets.

  International journal of clinical pharmacology and therapeutics 20070501

• Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070401

• Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.

  Journal of pharmacokinetics and pharmacodynamics 20070401

• Paliperidone: quo vadis?

  International journal of clinical practice 20070401

• Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.

  Drugs of today (Barcelona, Spain : 1998) 20070401

• Paliperidone (Invega) for schizophrenia.

  The Medical letter on drugs and therapeutics 20070312

• Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

  Schizophrenia research 20070201

• Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  Journal of clinical psychopharmacology 20070201

• Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

  Journal of clinical psychopharmacology 20070201

• FDA approves new antipsychotic.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070201

• Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.

  Clinical therapeutics 20070201

• Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.

  Annals of general psychiatry 20070101

• Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.

  Pharmacopsychiatry 20070101

• Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.

  Clinical neuropharmacology 20070101

• Paliperidone extended release.

  CNS drugs 20070101

• New drugs: paliperidone, dasatinib, and decitabine.

  Journal of the American Pharmacists Association : JAPhA 20070101

• New drug for schizophrenia.

  FDA consumer 20070101

• Possible neuroleptic malignant syndrome associated with paliperidone.

  The Journal of neuropsychiatry and clinical neurosciences 20070101

• Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.

  Arzneimittel-Forschung 20070101

• Paliperidone: the evidence of its therapeutic value in schizophrenia.

  Core evidence 20070101

• Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.

  Human psychopharmacology 20061201

• Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.

  Therapeutic drug monitoring 20061001

• Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.

  Pharmacogenomics 20061001

• Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

  Psychopharmacology 20060901

• Membrane transporter proteins: a challenge for CNS drug development.

  Dialogues in clinical neuroscience 20060901

• [Paliperidone].

  Medizinische Monatsschrift fur Pharmazeuten 20060801

• Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.

  Acta psychiatrica Scandinavica 20060701

• Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.

  Pharmacology, biochemistry, and behavior 20060601

• Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.

  Archives of pharmacal research 20060601

• [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].

  No to shinkei = Brain and nerve 20060601

• Risperidone in the treatment of bipolar mania.

  Neuropsychiatric disease and treatment 20060601

• Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20060503

• Intestinal uptake and biodistribution of novel polymeric micelles after oral administration.

  Journal of controlled release : official journal of the Controlled Release Society 20060310

• Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.

  Acta pharmacologica Sinica 20060301

• A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

  The American journal of psychiatry 20060301

• Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.

  Rapid communications in mass spectrometry : RCM 20060101

• Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.

  Journal of clinical psychopharmacology 20051201

• Plasma risperidone levels and clinical response in patients with first-episode psychosis.

  Journal of clinical psychopharmacology 20051201

• Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.

  Clinical pharmacology and therapeutics 20051101

• P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments.

  Human psychopharmacology 20051001

• Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.

  Therapeutic drug monitoring 20051001

• Risperidone plasma levels, clinical response and side-effects.

  European archives of psychiatry and clinical neuroscience 20050801

• Influence of age and gender on risperidone plasma concentrations.

  Journal of psychopharmacology (Oxford, England) 20050701

• Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.

  Clinical pharmacology and therapeutics 20050701

• Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

  The American journal of psychiatry 20050501

• Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.

  The international journal of neuropsychopharmacology 20050301

• Risperidone and breast-feeding.

  Journal of psychopharmacology (Oxford, England) 20050301

• Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

  International clinical psychopharmacology 20050301

• Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.

  Therapeutic drug monitoring 20050201

• The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

  Drug metabolism and disposition: the biological fate of chemicals 20050101

• Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.

  L'Encephale 20050101

• The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.

  The international journal of neuropsychopharmacology 20041201

• Identification and characterization of major degradation products of risperidone in bulk drug and pharmaceutical dosage forms.

  Journal of pharmaceutical and biomedical analysis 20040921

• A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma.

  Journal of analytical toxicology 20040901

• Plasma risperidone concentrations during combined treatment with sertraline.

  Therapeutic drug monitoring 20040801

• In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis.

  Clinical therapeutics 20040801

• QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

  Journal of psychopharmacology (Oxford, England) 20040601

• Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.

  British journal of clinical pharmacology 20040501

• Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.

  Psychiatry and clinical neurosciences 20040401

• Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry.

  Journal of chromatography. A 20040213

• Transfer of risperidone and 9-hydroxyrisperidone into human milk.

  The Annals of pharmacotherapy 20040201

• Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.

  Journal of child and adolescent psychopharmacology 20040101

• Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.

  Therapeutic drug monitoring 20031201

• Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.

  Therapeutic drug monitoring 20030601

• Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.

  Clinical therapeutics 20030601

• Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.

  Psychopharmacology 20030201

• Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.

  Journal of clinical pharmacology 20030201

• Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

• Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105

• Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.

  Journal of clinical pharmacology 20021201

• Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.

  Pharmacopsychiatry 20021101

• A colloidal graphite-coated emitter for sheathless capillary electrophoresis/nanoelectrospray ionization mass spectrometry.

  Analytical chemistry 20021015

• Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.

  Synapse (New York, N.Y.) 20021001

• Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020605

• Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

  The Journal of pharmacology and experimental therapeutics 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.

  Toxicology and applied pharmacology 20020415

• The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

  Pharmacopsychiatry 20020301

• Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.

  Psychopharmacology 20020201

• Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects.

  Journal of geriatric psychiatry and neurology 20020101

• Sequential changes in the plasma concentration of risperidone following intentional overdose.

  Clinical neuropharmacology 20020101

• Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

  Drug metabolism and disposition: the biological fate of chemicals 20011001

• Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.

  Therapeutic drug monitoring 20010601

• Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.

  European psychiatry : the journal of the Association of European Psychiatrists 20010201

• Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.

  Psychopharmacology 20010101

• Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.

  BMC pharmacology 20010101

• Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.

  Neuropsychobiology 20010101

• Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.

  Psychopharmacology 19991201

• Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

  The Journal of clinical psychiatry 19940501